Background: Recent studies have shown that approximately 1 in 6 women of reproductive age use potentially teratogenic medications. Since the pregnancy section in drug labeling is often inconsistent or incomplete, many pregnant women may inadvertently expose their fetus to potentially teratogenic drugs. Method: We examined the pregnancy section in the labeling of 6 potentially teratogenic drugs: thalidomide, isotretinoin, leflunomide, warfarin sodium, alprazolam, and lisinopril. We also reviewed regulatory guidelines that address issues regarding contraception method use. Results: The amount of information regarding contraception use in drug labeling varied. Occasionally, this information was not found altogether. Regulatory guidelines regarding contraception use, albeit useful, do not comprehensively cover all relevant areas. Conclusion: There is a need for an internationally harmonized regulatory guideline that clearly defines when, how, and what type of contraception methods should be used, as well as what type of contraception information should be included in the labeling.
BonatiMBortolusRMarchettiFRomeroMTognoniG. Drug use in pregnancy: an overview of epidemiological (drug utilization) studies. Eur J Clin Pharmacol. 1990;38(4):325–328.
DawJRHanleyGEGreysonDLMorganSG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2011;20(9):895–902.
4.
MitchellAAGilboaSMWerlerMMMedication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 2011(205):51.e51–58.
5.
SchwarzEBPostlethwaiteDAHungY-YArmstrongMA. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann Intern Med. 2007;147(6):370–376.
6.
HenshawSK. Unintended pregnancy in the United States. Fam Plann Perspect. 1998;30(1):24–29, 46.
7.
Centers for Disease Control and Prevention. PRAMS and unintended pregnancy. www.cdc.gov/prams/UP.htm. Accessed March 25, 2011.
8.
Food and Drug Administration. Title 21: food and drugs. In: Code of Federal Regulations. Washington DC: US Dept of Health and Human Services; 2011.
9.
SchwarzEBMaselliJNortonMGonzalesR. Prescription of teratogenic medications in United States ambulatory practices. Am J Med2005;118(11):1240–1249.
10.
ShrankWHAvornJ.Educating patients about their medications: The potential and limitations of written drug information. Health Aff2007;26(3):731–740.
NgEWChiruvoluPLevyGFAllanBRWyszynskiDF. Contraception language in informed consent forms: a survey of biopharmaceutical companies. Drug Information Journal. 2012;46(3):329–335.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals [ICH Harmonised Tripartite Guideline M3 (R2)]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf. Published June 11, 2009.
StahlOBoydHAGiwercmanARisk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries. J Natl Cancer Inst. 2011;103(5):398–406.
21.
WyszynskiDF. Pregnancy exposure registries: academic opportunities and industry responsibility. Birth Defects Res A Clin Mol Teratol. 2009;85(1):93-101.
LoWYFriedmanJM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol. 2002;100(3):465–473.
24.
Food and Drug Administration. FDA drug safety communication: risk of oral clefts in children born to mothers taking Topamax (topiramate). http://www.fda.gov/Drugs/DrugSafety/ucm245085.htm. Published March 4, 2011.
